Luca Issi
Stock Analyst at RBC Capital
(3.93)
# 631
Out of 5,008 analysts
205
Total ratings
50%
Success rate
10.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $435 → $500 | $459.58 | +8.79% | 28 | Sep 19, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $70 → $80 | $68.94 | +16.04% | 9 | Sep 4, 2025 | |
| ARGX argenx SE | Initiates: Outperform | $850 | $797.35 | +6.60% | 1 | Aug 25, 2025 | |
| RGNX REGENXBIO | Maintains: Outperform | $21 → $17 | $10.51 | +61.75% | 10 | Aug 8, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $25 → $21 | $20.44 | +2.74% | 5 | Aug 8, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $40 → $38 | $36.54 | +4.00% | 9 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $210 → $230 | $209.84 | +9.61% | 3 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $38 → $42 | $70.62 | -40.53% | 14 | Aug 5, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $4 → $5 | $9.24 | -45.89% | 1 | Jul 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $25 → $23 | $13.95 | +64.87% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $4.94 | -19.03% | 8 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.35 | +640.74% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $25.21 | -28.60% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $28 | $27.34 | +2.41% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $8.34 | +139.81% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $95 | $48.77 | +94.79% | 7 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.70 | +186.62% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.52 | +47.57% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $8.49 | +53.12% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $8.32 | +320.67% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $25.13 | +3.46% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $54.70 | +27.97% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $57.92 | -58.56% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $34.41 | +65.65% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $46.95 | +42.71% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $3.93 | +1.78% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $29.74 | +158.91% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $7.19 | +108.62% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.43 | +476.13% | 5 | Aug 7, 2024 |
Alnylam Pharmaceuticals
Sep 19, 2025
Maintains: Outperform
Price Target: $435 → $500
Current: $459.58
Upside: +8.79%
Ionis Pharmaceuticals
Sep 4, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $68.94
Upside: +16.04%
argenx SE
Aug 25, 2025
Initiates: Outperform
Price Target: $850
Current: $797.35
Upside: +6.60%
REGENXBIO
Aug 8, 2025
Maintains: Outperform
Price Target: $21 → $17
Current: $10.51
Upside: +61.75%
Intellia Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $20.44
Upside: +2.74%
Arrowhead Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $40 → $38
Current: $36.54
Upside: +4.00%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $209.84
Upside: +9.61%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Sector Perform
Price Target: $38 → $42
Current: $70.62
Upside: -40.53%
Fulcrum Therapeutics
Jul 30, 2025
Maintains: Sector Perform
Price Target: $4 → $5
Current: $9.24
Upside: -45.89%
Dyne Therapeutics
Jul 29, 2025
Maintains: Outperform
Price Target: $25 → $23
Current: $13.95
Upside: +64.87%
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $4.94
Upside: -19.03%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.35
Upside: +640.74%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $25.21
Upside: -28.60%
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $27.34
Upside: +2.41%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $8.34
Upside: +139.81%
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $48.77
Upside: +94.79%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.70
Upside: +186.62%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $11.52
Upside: +47.57%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $8.49
Upside: +53.12%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $8.32
Upside: +320.67%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $25.13
Upside: +3.46%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $54.70
Upside: +27.97%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $57.92
Upside: -58.56%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $34.41
Upside: +65.65%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $46.95
Upside: +42.71%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $3.93
Upside: +1.78%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $29.74
Upside: +158.91%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $7.19
Upside: +108.62%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.43
Upside: +476.13%